The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer

Al‐Akhrass, Hussein; Christou, Niki

doi:10.3390/cancers13122916

Cited by 9 publications

(9 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The target genes of many miRNAs are proto-oncogenes or tumor suppressor genes, and the abnormal expression of miRNAs is a common feature of tumorigenesis ( Al-Akhrass and Christou, 2021 ). We hope that the microRNA microarray can help us find a potential therapeutic approach for EGFR-positive CRC.…”

Section: Discussionmentioning

confidence: 99%

MiR-320d Inhibits Progression of EGFR-Positive Colorectal Cancer by Targeting TUSC3

Yunfen¹,

Qi²,

Wu³

2021

Front. Genet.

View full text Add to dashboard Cite

Background: The mechanism of miR-320d in EGFR-positive colorectal cancer (CRC) has not been fully elucidated. The aim of the present study was to explore the molecular mechanism of miR-320d in CRC.Methods: The miRNA microarray analysis was conducted to identify differential expressed miRNAs. The expression of miR-320d was validated using quantitative real-time PCR. EGFR-positive CRC cells were transfected with miR-320d mimic and inhibitor, after which cell proliferation, migration, and invasion were assayed. The relationship between miR-320d and TUSC3 was confirmed using bioinformatics and dual-luciferase reporter gene assays. Proteins involved in signaling pathways and the epithelial–mesenchymal transition were detected with Western blot.Results: We found that the miR-320d expression is associated with tumor size and distant metastasis in colorectal cancer. Overexpression of miR-320d in EGFR-positive HCT-116 and SW480 cells decreased not only the proliferation ability but also the invasion and migration ability. In addition, miR-320d had the ability to inhibit epithelial-to-mesenchymal transition. Luciferase assays revealed that miR-320d directly targets the 3′-UTR of TUSC3. TUSC3 was downregulated by miR-320d at both the protein and mRNA levels in EGFR-positive CRC cell lines.Conclusion: Generally, our results demonstrated that miR-320d could inhibit the malignant phenotype of EGFR-positive CRC through targeting TUSC3. The miR-320d might be a potential therapeutic target for EGFR-positive CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

MiR-320d Inhibits Progression of EGFR-Positive Colorectal Cancer by Targeting TUSC3

Yunfen¹,

Qi²,

Wu³

2021

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…MicroRNAs are found in all tissues and play a function in every cell type [7]. A large number of studies in CRC have also revealed that microRNA expression profiles change remarkably between normal tissues and tumors, were associated with drug resistance, as well as possess diagnostic, prognostic, and theranostic values [8][9][10][11]. Moreover, microRNAs play dual roles as oncogenes and tumor suppressors, which is the key function in tumorigenesis [12].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA Methylome Signature and Their Functional Roles in Colorectal Cancer Diagnosis, Prognosis, and Chemoresistance

Baharudin

Bakarurraini

Ismail

et al. 2022

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Despite significant advances in the diagnostic services and patient care, several gaps remain to be addressed, from early detection, to identifying prognostic variables, effective treatment for the metastatic disease, and the implementation of tailored treatment strategies. MicroRNAs, the short non-coding RNA species, are deregulated in CRC and play a significant role in the occurrence and progression. Nevertheless, microRNA research has historically been based on expression levels to determine its biological significance. The exact mechanism underpinning microRNA deregulation in cancer has yet to be elucidated, but several studies have demonstrated that epigenetic mechanisms play important roles in the regulation of microRNA expression, particularly DNA methylation. However, the methylation profiles of microRNAs remain unknown in CRC patients. Methylation is the next major paradigm shift in cancer detection since large-scale epigenetic alterations are potentially better in identifying and classifying cancers at an earlier stage than somatic mutations. This review aims to provide insight into the current state of understanding of microRNA methylation in CRC. The new knowledge from this study can be utilized for personalized health diagnostics, disease prediction, and monitoring of treatment.

show abstract

“…Hundreds of miRNA expression profiles have been demonstrated to offer at least the same potential for identifying biomarkers as profiling their mRNA or protein equivalents. The presence of miRNAs in serum and plasma has been consistently documented, and the use of miRNAs as minimally invasive biomarkers for the identification of colon cancer has shown promising results [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Tumor-Originated Exosomal hsa-miR-3937 as a Minimally Invasive Early Biomarker for Liquid Biopsy of Colorectal Cancer

Qiao

Wang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Exosomal microRNAs (miRNAs) have been linked to the genesis and progression of certain cancers. The role and regulation mechanism of cancer-derived exosomal miRNAs in CRC, however, remain unknown. Methods. To address this, we first used miRNA sequencing to describe the miRNA profiles of circulating exosomes in order to identify miRNAs that were differently expressed between patients with CRC and healthy controls. Transmission electron microscopy, nanoparticle tracking analysis (NTA), and western blot were used to analyze exosomes generated from CRC cells. CCK-8, wound healing, and Transwell tests were used to see whether exosomes affected CRC cell proliferation, metastasis, and apoptosis, respectively. We chose and identified hsa-miR-3937, which was abundant in tumor-generated exosomes, based on earlier RNA sequencing data of exosomes obtained and extracted from seven matched specimens of tumor tissues and surrounding normal tissues of CRC patients. Results. The role of hsa-miR-3937 in CRC cells was found, and silencing of hsa-miR-3937 decreased CRC cell invasion and migration in a Transwell experiment. Furthermore, we discovered that there was no link between hsa-miR-3937 expression and CRC cell apoptosis. Initially, it was discovered that BCL2L12 was the target gene of hsa-miR-3937, and the TCGA database highlighted the potential therapeutic relevance of BCL2L12. Furthermore, to identify hsa-miR-3937 as a biomarker of CRC, we used peripheral blood samples rather than patient tissues and extracted exosomes from plasma samples. To assess the expression levels and predictive usefulness of plasma exosomal hsa-miR-3937 in CRC, we performed RT-qPCR to identify hsa-miR-3937 levels in all samples. We also gathered clinicopathological information in order to look for links between aberrant hsa-miR-3937 expression and clinicopathological characteristics. The pathologic stage of CRC patients was linked to hsa-miR-3937 expression levels, and the same was true for the T stage. ROC curve study revealed that hsa-miR-3937 outperforms CEA and CA199. The combination of hsa-miR-3937, CEA, and CA199 exhibited the highest sensitivity for CRC diagnosis. Conclusions. Our findings show that the tumor-originated exosomal hsa-miR-3937 is a potential and effective liquid biopsy marker for colorectal cancer detection and therapy.

show abstract

The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer

Cited by 9 publications

References 122 publications

MiR-320d Inhibits Progression of EGFR-Positive Colorectal Cancer by Targeting TUSC3

MiR-320d Inhibits Progression of EGFR-Positive Colorectal Cancer by Targeting TUSC3

MicroRNA Methylome Signature and Their Functional Roles in Colorectal Cancer Diagnosis, Prognosis, and Chemoresistance

Tumor-Originated Exosomal hsa-miR-3937 as a Minimally Invasive Early Biomarker for Liquid Biopsy of Colorectal Cancer

Contact Info

Product

Resources

About